

Creativity. Capability. Capital.

AusBiotech2011
AUSTRALIA'S BIOTECHNOLOGY CONFERENCE



16 to 19 October 2011
Adelaide Convention Centre, South Australia
www.ausbiotech2011.com.au



AUSBIOTECH 2011 CONFERENCE SPEAKERS' PROFILE

Paul Kelly
General Partner & Executive Director
One Ventures, Australia

Paul serves as a member of the Investment Committee and Executive Director of the Manager providing representation for OneVentures' funds and investee companies both here in Australia and on the east coast of the United States. An Australian physician, serial entrepreneur and experienced biotechnology and life sciences executive, he currently resides in Boston, has over 25 years experience in clinical medicine and medical science and 15 years experience in commercialising life science related technologies in Australia, Europe and North America.



Paul has over recent years assisted and led early-stage and mid stage companies achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses.

Paul joined the OneVentures team in June 2008 following the merger of Andover Venture Partners and OneVentures. Paul was most recently CEO of Medcenter Holdings Inc. a Latin America based on-line pharmaceutical marketing company, a position he held until December 2007. Previously he served as President and CEO of Orchid Cellmark (Nasdaq:ORCH), the world's leading provider of genetic testing services, from June 2003 until March 2006. During his tenure at both companies he developed and implemented major operational and strategic restructurings. From 1995 to 2001, Dr. Kelly served as CEO of Gemini Genomics (Nasdaq:GMNI), a clinical genomics company which he co-founded in 1995 to discover and commercialize novel gene-based targets. At Gemini, Dr. Kelly positioned the company for one of the UK's largest biotechnology IPOs, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world's leading research institutions. In 2001, Dr. Kelly oversaw the company's successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over \$250M, after which he served for a short period as Executive Vice President.

Before becoming a biotechnology executive, Dr. Kelly had a distinguished career as a researcher and physician specializing in endocrinology at St Vincent's Hospital, Sydney, Australia. While serving as a Research Physician at the Garvan Institute for Medical Research in Sydney, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders.

Paul has co-founded a number of other companies in the health sciences and technology arena, including MEARS Technologies, Inc. and AgaMatrix, Inc (a consumer medical device company), all based in the greater Boston area.

Paul has served on national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Dr. Kelly is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Honours), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians. He also serves on the UNSW Medicine Deans Advisory Group.